Thursday 23rd August 2018
|Text too small?|
Ebos Group boosted annual earnings in line with its forecast even though revenue fell, as the pharmaceutical and animal health products company increased margins and benefited from acquisitions.
Underlying earnings before interest, tax, depreciation, amortisation on a constant currency basis increased 10.3 percent to $272.4 million in the year ended June 30, in line with its forecast for 10 percent growth. Revenue slipped 2.5 percent to $7.6 billion. The company's healthcare business lifted its ebitda profit margin to 3.28 percent from 2.9 percent, while the animal care unit expanded margins to 12.08 percent from 10.57 percent.
Ebos has lifted ebitda 55 percent since 2014 as it pursued acquisitions across New Zealand and Australia and has invested $33.6 million on in the past year. Its investments included a 14 percent stake in Australia's leading digital medication management company MedAdvisor, the acquisition of New Zealand's leading footcare consumer brand Gran's Remedy, and the purchase of the management company of Australian pharmacy retail group Ventura Health. In addition, it integrated HPS, Australia's largest provider of outsourced pharmacy services to hospitals, which it bought at the end of last financial year, and launching its premium pet-food brand Black Hawk into the New Zealand market.
"We are pleased to once again report strong financial results," chief executive John Cullity said in a statement. The results "reflect a consistent positive momentum across both our healthcare and animal care businesses."
Ebos said it is confident of further profit growth in the current 2019 financial year on an underlying, constant currency basis. It will provide a performance update at its annual shareholder meeting on Oct. 16.
The company will pay a final dividend of 35.5 cents per share on Oct. 12, taking its annual dividend to 68.5 cents, ahead of 63 cents in 2017.
In its healthcare business, ebitda increased 10.4 percent to $235.9 million on a constant currency basis, as revenue fell 2.3 percent to $7.2 billion due to a $364 million reduction in hepatitis C medicine sales.
Animal care ebitda grew 9 percent to $49.8 million on a constant currency basis as revenue slipped 5.1 percent.
The company said Black Hawk sales in Australia grew 23 percent, and was one of Australia's fastest growing premium pet food brands with a leading market position in the pet specialty retail channel.
"Total animal care revenue declined for the year principally due to the business ceasing sales of low-margin wholesale products to a major Australian retail chain and discontinuing sales of other products upon the introduction of Black Hawk into New Zealand," Ebos said. "The business has strategically realigned its focus on developing its own brands to drive greater margin and shareholder value."
Ebos signalled plans to report earnings in Australian dollars in the future, given about 82 percent of its earnings are now generated in Australia and its results are significantly impacted by movements in the currencies.
The shares last traded at $21, having gained 13 percent so far this year.
No comments yet
NZ dollar rises on optimism for China-US trade deal
Steel & Tube recovery to include $5.6M of 2nd-half cost savings
Open Country challenges validity of Fonterra's 2018 milk price
Guest night growth slows; overseas visitors spent less time in North Island
Nib NZ first-half earnings slide 30% as claims outpace policy growth
Customer satisfaction in NZ banks rises despite Australian scandals
Perky services sector in Janary soothes fears over cooling economy
PFI doubles 2018 profit on valuation gains, underlying earnings fall short
Steel & Tube turnaround continues with 49% jump in first-half net profit
February 18th Morning Report